Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Merus N.V. (MRUS : NSDQ)

• Company Description    Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands. Number of Employees: 175

• Price / Volume Information    Yesterday's Closing Price: $16.80 Daily Weekly Monthly 20 Day Moving Average: 325,349 shares Shares Outstanding: 43.55 (millions) Market Capitalization: $731.64 (millions) Beta: 1.11 52 Week High: $33.09 52 Week Low: $14.78 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -24.97% -17.84% 12 Week -37.24% -29.47% Year To Date -47.17% -35.46%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL YALELAAN 62 - UTRECHT,P7 3584 NLD ph: 31-0-30-253-8800 fax: - enquiries@merus.nl http://www.merus.nl

• General Corporate Information    Officers Sven (Bill) Ante Lundberg - President; Chief Executive Officer and Principal Anand Mehra - Chairman of the Board of Directors Harry Shuman - Chief Accounting Officer Mark T. Iwicki - Director Len Kanavy - Director Peer Information Merus N.V. (CORR.) Merus N.V. (RSPI) Merus N.V. (CGXP) Merus N.V. (BGEN) Merus N.V. (GTBP) Merus N.V. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N5749R100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 43.55 Most Recent Split Date: (:1) Beta: 1.11 Market Capitalization: $731.64 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.65 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.48 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.46 Price/Cash Flow: - Price / Sales: 13.96 EPS Growth vs. Year Ago Period: -53.57% vs. Previous Quarter: -26.47% Sales Growth vs. Year Ago Period: 39.58% vs. Previous Quarter: -20.76% ROE 03/31/22 - -29.02 12/31/21 - -27.26 09/30/21 - -39.37 ROA 03/31/22 - -18.73 12/31/21 - -16.76 09/30/21 - -22.03 Current Ratio 03/31/22 - 6.17 12/31/21 - 5.90 09/30/21 - 4.47 Quick Ratio 03/31/22 - 6.17 12/31/21 - 5.90 09/30/21 - 4.47 Operating Margin 03/31/22 - -143.77 12/31/21 - -135.65 09/30/21 - -173.15 Net Margin 03/31/22 - -143.77 12/31/21 - -135.65 09/30/21 - -185.10 Pre-Tax Margin 03/31/22 - -143.58 12/31/21 - -135.57 09/30/21 - -184.41 Book Value 03/31/22 - 6.83 12/31/21 - 8.15 09/30/21 - 5.30 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©